全文获取类型
收费全文 | 39901篇 |
免费 | 2365篇 |
国内免费 | 1069篇 |
专业分类
耳鼻咽喉 | 116篇 |
儿科学 | 1466篇 |
妇产科学 | 1404篇 |
基础医学 | 4829篇 |
口腔科学 | 402篇 |
临床医学 | 3425篇 |
内科学 | 7108篇 |
皮肤病学 | 372篇 |
神经病学 | 3633篇 |
特种医学 | 538篇 |
外国民族医学 | 6篇 |
外科学 | 3093篇 |
综合类 | 5696篇 |
现状与发展 | 6篇 |
预防医学 | 1711篇 |
眼科学 | 168篇 |
药学 | 6427篇 |
15篇 | |
中国医学 | 1408篇 |
肿瘤学 | 1512篇 |
出版年
2024年 | 45篇 |
2023年 | 340篇 |
2022年 | 690篇 |
2021年 | 1132篇 |
2020年 | 954篇 |
2019年 | 954篇 |
2018年 | 940篇 |
2017年 | 1067篇 |
2016年 | 1081篇 |
2015年 | 1183篇 |
2014年 | 2098篇 |
2013年 | 2631篇 |
2012年 | 2021篇 |
2011年 | 2332篇 |
2010年 | 1930篇 |
2009年 | 1820篇 |
2008年 | 1867篇 |
2007年 | 1854篇 |
2006年 | 1810篇 |
2005年 | 1662篇 |
2004年 | 1341篇 |
2003年 | 1267篇 |
2002年 | 1061篇 |
2001年 | 992篇 |
2000年 | 890篇 |
1999年 | 747篇 |
1998年 | 656篇 |
1997年 | 692篇 |
1996年 | 644篇 |
1995年 | 557篇 |
1994年 | 570篇 |
1993年 | 507篇 |
1992年 | 511篇 |
1991年 | 474篇 |
1990年 | 481篇 |
1989年 | 399篇 |
1988年 | 339篇 |
1987年 | 300篇 |
1986年 | 312篇 |
1985年 | 364篇 |
1984年 | 310篇 |
1983年 | 228篇 |
1982年 | 255篇 |
1981年 | 222篇 |
1980年 | 177篇 |
1979年 | 159篇 |
1978年 | 130篇 |
1977年 | 94篇 |
1976年 | 72篇 |
1975年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
目的:探讨甲状旁腺激素(PTH)对大鼠牵张成骨(DO)过程中ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因表达的影响。方法30只雄性大鼠制备大鼠下颌骨DO模型。随机分5组,每组6只。第1组(只有牵张无PTH),术后8周取材,应用HE染色及微CT检测,以确定成骨情况。第2组(有牵张无PTH),第3组(有牵张有PTH),第4组(无牵张有PTH),第5组(对照组:无牵张无PTH)。2、3、4组及对照组术后1周取材,RT-PCR测定ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因的表达。结果第1组,新骨形成,骨质充满牵张区,骨质连续,大鼠建模成功。RT-PCR检测结果显示,2、3、4组与对照组比较,OPN、COL1、RUNX2、ALP基因表达有明显提高(P<0.05),其中第3组最为明显。ONC、C-FOS、VEGF基因2、3、4组与对照组比较差异无统计学意义(P>0.05)。结论 PTH在 DO 过程中,间歇性给以 PTH的作用只有在牵张期发挥作用,其对 OPN、COL1、RUNX2、ALP基因表达能够获得理想的协同作用。 相似文献
4.
5.
Shafqat R. Chaudhry Ilana S. Lendvai Sajjad Muhammad Philipp Westhofen Johannes Kruppenbacher Lukas Scheef Henning Boecker Dirk Scheele Rene Hurlemann Thomas M. Kinfe 《Brain stimulation》2019,12(3):643-651
Objective
To assay peripheral inter-ictal cytokine serum levels and possible relations with non-invasive vagus nerve stimulation (nVNS) responsiveness in migraineurs.Methods
This double-blinded, sham-controlled study enrolled 48 subjects and measured headache severity, frequency [headache days/month, number of total and mild/moderate/severe classified attacks/month], functional state [sleep, mood, body weight, migraine-associated disability] and serum levels of inflammatory markers [inter-ictal] using enzyme-linked immunoassays at baseline and after 2 months of adjunctive nVNS compared to sham stimulation and suitably matched controls.Results
No significant differences were observed at baseline and after 2 months for headache severity, total attacks/month, headache days/month and functional outcome [sleep, mood, disability] between verum and sham nVNS. However, the number of severe attacks/month significantly decreased in the verum nVNS group and circulating pro-inflammatory IL-1β was elevated significantly in the sham group compared to nVNS. Levels of anti-inflammatory IL-10 were significantly higher at baseline in both groups compared to healthy controls, but not at 2 months follow-up [p?<?0.05]. Concentrations of high-mobility group box-1 (HMGB-1), IL-6, tumor-necrosis factor-α (TNF-α), leptin, adiponectin, ghrelin remained unchanged [p?>?0.05]. No severe device-/stimulation-related adverse events occurred.Conclusion
2 months of adjunctive cervical nVNS significantly declined the number of severe attacks/month. Pro-inflammatory IL-1β plasma levels [inter-ictal] were higher in sham-treated migraine patients compared to verum nVNS. However, pro- [IL-6, HMGB-1, TNF-α, leptin] and anti-inflammatory [IL-10, adiponectin, ghrelin] mediators did not differ statistically. Profiling of neuroinflammatory circuits in migraine to predict nVNS responsiveness remains an experimental approach, which may be biased by pre-analytic variables warranting large-scale biobank-based systematic investigations [omics]. 相似文献6.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
7.
8.
刘彦鹏 《中国卫生标准管理》2020,(5):95-97
目的探讨参附注射液对老年重症肺炎疗效及N末端B型利钠肽原(NT-pro BNP)的影响。方法选择2016年6月—2019年6月医院收治的老年重症肺炎患者80例,以随机数表法将其分为两组,即对照组与研究组各40例。对照组患者接受常规对症治疗,研究组在此基础上应用参附注射液治疗。对比两组临床疗效,治疗前与治疗3 d、5 d时血浆NT-pro BNP水平,以及不良反应情况。结果研究组治疗的总有效率为95.00%,高于对照组77.50%(P<0.05)。治疗后3 d与5 d时研究组血浆NT-pro BNP水平均低于对照组(P<0.01)。两组治疗期间均未见明显的药物不良反应。结论参附注射液能够有效提高老年重症肺炎患者的疗效,调节脑钠肽水平。 相似文献
9.
10.